Printable PDF Version

Program at a Glance

Saturday, April 18, 2020
8:00 a.m. to 5:00 p.m.Registration Desk Open
8:00 a.m. to 9:00 p.m.Morning Workshop Registration
9:00 a.m. to 4:00 p.m.FD-1 Fields, Filters, and Fun: Incorporating Creativity and Craft Into Database Literature Searches
9:00 a.m. to 12:00 p.m.AM-1 Estimating Health Care Costs Using Health Administrative Data and Phase-of-Care Costing
9:00 a.m. to 12:00 p.m.AM-2 Delving into the Literature: What Does the Evidence Really Say?
9:00 a.m. to 12:00 p.m.AM-3 Conducting Economic Evaluations in Child Healths in Child Health
9:00 a.m. to 12:00 p.m.AM-4 When Off-the-Rack Doesn't Fit: Alternative Methods for Estimating Preferences for Specific Health Conditions
1:00 p.m. to 4:00 p.m.PM-1 Rapid Reviews: From Decision Problem to Research and Decision-Making
1:00 p.m. to 4:00 p.m.PM-2 Applied Machine Learning for Health Data: Fundamental Concepts and Hands-On Practical Application
1:00 p.m. to 4:00 p.m.PM-3 Designing Research to Inform Decision-Making Using Value of Information Analyses
1:00 p.m. to 4:00 p.m.PM-4 Supporting Decision-Making in an Uncertain Future: A Hands-On Introduction to Horizon Scanning in Health Technology Management
1:00 p.m. to 4:00 p.m.Roundtable Discussion It’s a Patient Takeover! Blue-Skying Patient Engagement in HTA/HTM
Sunday, April 19, 2020
8:00 a.m. to 7:00 p.m. Registration Desk Open
8:00 a.m. to 9:00 a.m.Morning Workshop Registration
9:00 a.m. to 4:00 p.m.FD-2 NMA, MAIC, STC, PSM: Understanding the Various Indirect Treatment Comparison Methods and Which Method Should Be Used to Support HTA and Reimbursement Submissions
9:00 a.m. to 12:00 p.m.AM-5 An Introduction to Health Technology Assessment and Health Technology Management
9:00 a.m. to 12:00 p.m.AM-6 Introduction to Decision Modelling Using R
9:00 a.m. to 12:00 p.m.AM-7 Plain Language and Clearer Communication: Making Health Research Make Sense
9:00 a.m. to 12:00 p.m.AM-8 Combining Different Types of Evidence on Effectiveness, Implementation, and Views to Better Understand Complex Interventions
9:00 a.m. to 12:00 p.m.AM-9 Finding the Evidence: Practical Tools for Literature Searching
9:00 a.m. to 12:00 p
.m.
AM-10 Diagnostic Test Accuracy Meta-Analysis
1:00 p.m. to 4:00 p.m.PM-5 Pan-Canadian Pharmaceutical Alliance Update
1:00 p.m. to 4:00 p.m.PM-6 Reducing Uncertainty: The Need for Qualitative Research in Evidence-Informed Decision-Making
1:00 p.m. to 4:00 p.m.PM-7 From Lingo to Application: The Use of Confounder Summary Scores (Propensity Scores and Disease Risk Scores) in Health Technology Assessment Based on Real-World Data
1:00 p.m. to 4:00 p.m.PM-8 Health Technology Management Associated With Novel Clinical Trials Designs
1:00 p.m. to 4:00 p.m.PM-9 Survival Analysis and Decision Modelling in R
1:00 p.m. to 4:00 p.m.PM-10 Finding the Grey: Searching for Regulatory and Safety Information on Pharmaceuticals and Medical Devices
1:00 p.m. to 4:00 p.m.PM-11 — A Concise Guide on How to Calculate the Cost-Effectiveness Estimates and Characterize Uncertainty Using Person-Level Data
4:00 p.m. to 5:00 p.m.Student Meet and Greet
4:00 p.m. to 5:00 p.m.Patient Group Meet and Greet
5:00 p.m. to 7:00 p.m.Welcome Reception and Scientific Poster Exhibition
Monday, April 20, 2020
7:30 a.m. to 5:00 p.m.Registration Desk Open
7:30 a.m. to 9:00 a.m. Buffet Breakfast
7:45 a.m. to 8:45 a.m.Breakfast Session M1 Decision Aids: Tools to Reduce Uncertainty in Diagnostic Imaging
• Dr. Martin Reed, The Children’s Hospital of Winnipeg
• Anna Cooper Reed, University of Toronto
7:45 a.m. to 8:45 a.m.Breakfast Session M2 Pharmaceutical Pricing Reform in Canada: An Overview of the PMPRB’s New Price Review Process
• Dr. Etienne Gaudette, Patented Medicine Prices Review Board (PMPRB)
7:45 a.m. to 8:45 a.m.Breakfast Session M3 Nordic Decision-Making: Real-World Data and HTA
• Kirk Geale, Umeå University and Quantify Research
9:00 a.m. to 9:30 a.m.Official Opening
9:30 a.m. to 10:45 a.m.Opening Plenary
Decision-Making In An Age Of Uncertainty
Uncertainty is a fact of life for every decision-maker in the health care system, whether a patient, health care provider, policy-maker, administrator, industry representative, or payer. Rarely are all the facts available when a new drug, medical device, diagnostic tool, or surgical intervention is introduced. It sometimes seems that the situation is getting worse as more and more innovative products, curative therapies, and disruptive technologies enter the market. In this session, speakers from different parts of the health system will lay out the challenges and opportunities they see in this age of uncertainty and what they need from HTA and HTM bodies to thrive despite uncertainty.
10:45 a.m. to 11:15 a.m.Network Break
11:15 a.m. to 12:30 p.m. Concurrent Session A1 – Panel Discussion
Reducing Uncertainty and Driving the Uptake of Biosimilars: Lessons From the pan-Canadian Oncology Biosimilars Initiative
• Kathy Vu, Cancer Care Ontario
• Marc Geirnaert, CancerCare Manitoba
• M.J. DeCoteau, Rethink Breast Cancer
• Lisa Maslanka, Amgen Canada Inc.
• Dr. Leta Forbes, Durham Regional Cancer Centre and Cancer Care Ontario
11:15 a.m. to 12:30 p.m. Concurrent Session A2 – Panel Discussion
Value- and Outcome-Based Agreements in Medical Devices to Manage Uncertainty
• Frederic Rupprecht, Johnson & Johnson Medical Device Companies
• Dr. Harindra Wijeysundera, CADTH
• Erik Hellsten, Health Quality Ontario
• Dr. Fiona Miller, University of Toronto
11:15 a.m. to 12:30 p.m. Concurrent Session A3 – Panel Discussion
Testing for the Age of Precision Medicine: Uncertainty, Challenges, and Future Directions
• Monette Greenway, Precision Rx-Dx
• Dr. Tracy Stockley, University Health Network
• Dr. Tania Stafinski, University of Alberta
• James (Jim) Slater, Provincial Health Services Authority, British Columbia
• Julian Nam, Hoffmann-La Roche Ltd.
12:30 p.m. to 1:30 p.m.Networking Lunch
1:30 p.m. to 2:45 p.m.Concurrent Session B1 – Oral Presentations
Addressing Uncertainty
Decision-Making in the Face of Uncertainty: Experiences of Neurologists and Parents in the Use of Medical Cannabis for Children With Drug-Resistant Epilepsy
• Jesse Elliott, University of Ottawa
Leveraging Automation in Health Technology Assessment: Implementation and Its Impact on the Characterization of Uncertainty
• Daniel Wagner, University of Calgary
The Cost of Uncertainty: The Burden of Care of Failed Extubation in Intensive Care Units and Ways Forward
• Sasha van Katwyk, Ottawa Hospital Research Institute
Proton Beam Therapy at a Canadian Centre: Untangling Uncertainty Using a Budget Impact Analysis
• Dr. David Felipe Forero, McGill University Health Centre
1:30 p.m. to 2:45 p.m.Concurrent Session B2 – Oral Presentations
Artificial Intelligence
Artificial Intelligence in Outcomes Research: A Systematic Review to Inform Decision-Makers
• Dr. Pooyeh Graili, Quality HTA
Measuring the Uptake and Adoption of Artificial Intelligence Tools to Support Advanced Imaging Modalities in Canada
• Andra Morrison, CADTH
Optimizing the Value of Artificial Intelligence: Anticipating a New Level of Complexity
• Hassane Alami, INESSS
• Dr. Michèle de Guise, INESSS
1:30 p.m. to 2:45 p.m.Concurrent Session B3 – Oral Presentations
Hot Topics
Vaccine Hesitancy: A Conceptual Model for Understanding the Factors that Influence Vaccine Decision-Making of Parents With Young Children
• Umair Majid, University of Toronto
Under the Hood of Product Listing Agreements: The Continuing Evolution of the Non-Insured Health Benefits Product Listing Agreements Invoicing System
Andrew Portolesi, Indigenous Services CanadaPharmaceutical Pricing Reform in Canada: A New Role for Health Technology Assessments
• Dr. Étienne Gaudette, Patented Medicine Prices Review Board
The Cost “Changing the Game”: An Impact Assessment of CAR T-Cell Therapy
• Scott Gavura, Cancer Care Ontario
1:30 p.m. to 2:45 p.m.Concurrent Session B4 – Oral Presentations
Biosimilars
How Extrapolation of Indications Is Applied in the Regulatory Approval of Oncology Biosimilars
• Sean Hopkins, Cancer Care Ontario
Biosimilars in Canada: Challenges and Opportunities
• Jared Berger, PMPRB
In an Era of Biosimilars, Can Originator Infliximab Pricing Remain Competitive in Treating Inflammatory Bowel Disease?
• Dr. Naazish Bashir, The Hospital for Sick Children (SickKids)
1:30 p.m. to 2:45 p.m.Concurrent Session B5 – Oral Presentations
From Hta To Htm
How Can Policy Analysis Complement HTA in Supporting Evidence-Informed Decision-Making?
• Jonathan Harris, CADTH
Swiss Federal Office of Public Health Disinvestment HTA Program
• Dr. Goedele van Haasteren, Swiss Federal Office of Public Health
Filling the Evidence Gap: The Role of Real-World Data in Guiding the Rational Dispersion of New Disruptive Technologies
• Laurie Lambert, INESSS
Building a Reassessment Framework for Cancer Drugs: Lessons Learned From the CanREValue Collaboration Mock Reassessment Exercise
• Wei Fang Dai, Cancer Care Ontario
1:30 p.m. to 2:45 p.m.Concurrent Session B6 – Oral Presentations
Patient And Public Engagement
(Re)Defining Legitimacy? Expertise and Public and Patient Involvement in Canadian Drug Assessment
• Dr. Katherine Boothe, McMaster University
Understanding Primary Care Patients' Preferred Roles and Decisions in an Era of Uncertainty and Increased Health Technology
• Prof. Vidhi Thakkar, University of Toronto
A Public Advisory on HTA Decisions: An Opportunity to Help Determine Pharmacare’s Essential Medicines List?
• Colene Bentley, BC Cancer Research Centre
Patient Organizations’ Vision for Patient Engagement in New Product Reviews
• David Page, Canadian Hemophilia Society
1:30 p.m. to 2:45 p.m.Concurrent Session B7 – Oral Presentations
Oncology
The Cost-Effectiveness of Replacing Mammography With Tomosynthesis for Breast Cancer Screening in British Columbia
• Dr. Sonya Cressman, BC Cancer Research Centre
Developing the Breast Utility Instrument from the EORTC QLQ-C30 and the EORTC QLQ-BR45 to Measure Patient Preferences in Breast Cancer: Confirmatory Factor Analysis
• Teresa Tsui, Toronto Health Economics and Technology Assessment (THETA) Collaborative
“Prepared to Live With the Unknown”: Adult Cancer Patients’ Experiences with Uncertainty in Decision-Making About Learning Incidental Results From Genomic Sequencing
• Chloe Mighton, University of Toronto
Exploring Health Care Providers’ Perspective on the Clinical Utility of Cell-Free DNA Testing
• Salma Shickh, St. Michael’s Hospital
2:45 p.m. to 3:15 p.m.Networking Break
3:15 p.m. to 4:30 p.m.Concurrent Session C1 – Panel Discussion
Getting Real About Real-world Evidence: Critical Steps And Essential Components For Building An Effective Program In Real-World Evidence Generation
• Dr. Winson Cheung, Cancer Control Alberta
• Dr. Darren Brenner, University of Calgary
• Devon Boyne, University of Calgary
• Christie Farrer, Alberta Health Services
3:15 p.m. to 4:30 p.m.Concurrent Session C2 – Panel Discussion
Has Car T-cell Therapy Changed The Drug Review Paradigm In Canada?
• Dr. Christopher McCabe, Institute of Health Economics
• Dr. Michèle de Guise, INESSS
• Dr. Elizabeth Lye, Lymphoma Canada
• Scott Gavura, Cancer Care Ontario
• Dr. Donna Wall, The Hospital for Sick Children (SickKids)
3:15 p.m. to 4:30 p.m.Concurrent Session C3 – Panel Discussion
Is Clinician Participation In The CADTH Pan-canadian Oncology Drug Review (pCODR) Impactful On Decision-making?
• Martine Elias, Myeloma Canada
• Dr. Maureen Trudeau, Sunnybrook Health Sciences Centre
• Dr. Tom Kouroukis, McMaster University
• Kim Yoong, Astellas Pharma Canada Inc.
• Marc Geirnaert, Cancer Care Manitoba
3:15 p.m. to 4:30 p.m.Concurrent Session C4 – Panel Discussion
Environmentally Preferable Health Technologies: The Role Of HTA And Management
• Dave Marchand, CADTH
• Prof. Beate Sander, University of Toronto
• Prof. Steven Young, University of Waterloo
• Dr. Edward Xie, University of Toronto
• Prof. Fiona Miller, University of Toronto
3:15 p.m. to 4:30 p.m.Concurrent Session C5 – Panel Discussion
CADTH And Patients: A Paradigm Shift To Seeking Patient And Community Partnership
• Zal Press, CADTH Patient and Community Advisory Committee
• Marney Paradis, CADTH Patient and Community Advisory Committee
• Dr. Michelle Mujoomdar, CADTH
• Sarah Berglas, CADTH
• Tamara Rader, CADTH
3:15 p.m. to 4:30 p.m.CONCURRENT SESSION C6 – PANEL DISCUSSION
Medical Cannabis — Consensus Guidance on the Use of Cannabinoids and Opioids in Chronic Pain
• Aaron Sihota, University of British Columbia
• Dr. Colleen O’Connell, Stan Cassidy Centre for Rehabilitation
• Dr. Mark Ware, Canopy Growth Corporation
• Dr. Paul Oh, University Health Network
• Dr. Judith Glennie, J.L. Glennie Consulting Inc.
3:15 p.m. to 4:30 p.m.CONCURRENT SESSION C7 – PANEL DISCUSSION
Creating an Outcomes-Based Agreement: A Canadian Case Study
• Sang Mi Lee, pan-Canadian Pharmaceutical Alliance (pCPA) Office
• Angie Wong, Ontario Public Drug Programs
• Andre Vidal Pinheiro, Takeda
6:00 p.m. to 9:00 p.m.Social Event – Dinner In The Clouds
Join us at the CN Tower for a spectacular evening of fun, food, and breathtaking views. You’ll arrive at 346 metres above-ground to the LookOut Level, where you’ll take in the unparalleled scenes of Toronto through the new floor-to-ceiling panoramic Window Walls. From there, you can look straight down below you through the Glass Floor. Enjoy hors d’oeuvres and dinner from the CN Tower’s award-winning menu that showcases the best Canadian- and Ontario-specific food and beverages. Prepare yourself for an informal networking evening with amazing sights, delicious food, and unique entertainment. Buses leave from the Sheraton Centre at 5:30 p.m.
Tuesday, April 21, 2020
7:30 a.m. to 5:00 p.m.Registration Desk Open
7:30 a.m. to 9:00 a.m.Buffet Breakfast
7:45 a.m. to 8:45 a.m.Breakfast Session T1
Implementing An Expanded Mandate For National Vaccine Decision-making In Canada
• Dr. Matthew Tunis, Public Health Agency of Canada
• Dr. Shelley Deeks, Public Health Ontario
• Dr. Beate Sander, University Health Network
• Man Wah Yeung, Public Health Agency of Canada
7:45 a.m. to 8:45 a.m.Breakfast Session T2
Drugs for Rare Diseases: The Promise Precision Medicine Has in Creating Certainty in an Uncertain World
• Rob Burtch, Cystic Fibrosis Canada
• Tammy Moore, ALS Society of Canada
• Dr. Felix Ratjen, The Hospital for Sick Children (SickKids)
• Dr. Larry Lynd, University of British Columbia
7:45 a.m. to 8:45 a.m.Breakfast Session T3
A Case Study on the Spread of New Technology: Using Evidence and Partnership to Improve Clinical Delivery, Outcomes, and Costs of Transcatheter Aortic Valve Implantation (TAVI)
• Graham Woodward, CorHealth Ontario
• Mirna Rahal, CorHealth Ontario
• Jana Jeffrey, CorHealth Ontario
• Lauren Bell, Plexxus
• Safina Allidina, Plexxus
7:45 a.m. to 8:45 a.m.Breakfast Session T4
Can Ontario Administrative Data at ICES-Data & Analytic Services (DAS) Be Used to Address Uncertainty?
• Soo Jin Seung, HOPE Research Centre, Sunnybrook Research Institute
• Ryan Walton, AstraZeneca Canada
• Refik Saskin, ICES-DAS
• Dr. William Evans, McMaster University
7:45 a.m. to 8:45 a.m.Breakfast Session T5
The Next Generation of Health Leaders: How Evidence and Ingenuity Will Transform the (Uncertain) Future of Health Care
• Evelyn Pyper, Janssen Inc.
• Dr. Zayna Khayat, SE‒Saint Elizabeth Health
• Diana Martins, Ontario Drug Policy Research Network
9:00 a.m. to 10:15 a.m.Concurrent Session D1 – Panel Discussion
Therapeutic Vaccines: Managing the Uncertainty of the Post-Regulatory Process
• Dr. Matthew Tunis, Public Health Agency of Canada
• Brent Fraser, CADTH
• Heather Logan, CADTH
• Dr. Trevor Richter, CADTH
9:00 a.m. to 10:15 a.m.CONCURRENT SESSION D2 – PANEL DISCUSSION
Addressing Uncertainties to Improve the Successful Management of HIV
• Dr. Judith Glennie, J.L. Glennie Consulting Inc.
• Ron Rosenes, HIV/AIDS Legal Network
• Dr. Francisco Ibáñez-Carrasco, Dalla Lana School of Public Health, University of Toronto
• Muluba Habanyama, Canadian Foundation for AIDS Research
9:00 a.m. to 10:15 a.m.Concurrent Session D3 – Panel Discussion
Gene Therapies: What Happens After the Reimbursement Recommendation?
• Andrea Lau, PDCI Market Access Inc.
• Wayne Critchley, Global Public Affairs
• Steven Hill, PTC Therapeutics Canada
• Dr. Annette Hay, Queen’s University
• Carolyn Bell, British Columbia Ministry of Health
9:00 a.m. to 10:15 a.m.Concurrent Session D4 – Panel Discussion
How Public Private Philanthropic Partnerships are Changing Funding and Evidence Generation in Alberta?
• Dr. Lawrence Richer, University of Alberta
• Mehmood Alibhai, Boehringer Ingelheim
• Jamie Bliss, University Hospital Foundation
• Norm Berberich, Takeda Canada
10:15 a.m. to 10:45 a.m.Networking Break
10:45 a.m. to 12:00 p.m.Concurrent Session E1 – Oral Presentations
Mental Health
Patterns of Antipsychotic Drug Use Before Initiation of Long-Acting Injectable Antipsychotic Drugs
• Donica Janzen, University of Manitoba
Quantifying the Burden of Treatment-Resistant Depression in Ontario: Shedding Light on an Important Mental Health Issue
• Dr. Roger McIntyre, University of Toronto
Dementia Villages: An Emerging Care Concept in Canada?
• Jonathan Harris, CADTH
Usability of Information and Communication Technologies for Dementia: A Systematic Literature Review
• Dr. Antonio Miguel-Cruz, University of Alberta
• Dr. Lili Liu, University of Waterloo
10:45 a.m. to 12:00 p.m.Concurrent Session E2 – Oral Presentations
Applied Health Economics
Universal Screening of Newborns for Biliary Atresia: A Cost-Effectiveness Comparison of Alternative Strategies
• Lisa Masucci, University of Toronto
Modelling to Support Health Technology Decision-Making in British Columbia: The Case of Universal Mismatch Repair Reflex Testing for Lynch Syndrome
• Dr. Shahzad Ghanbarian, University of British Columbia
Methodological Considerations to Address the Uncertainty Associated With Economic Evaluations for Antimicrobial-Resistant Bacteria Prevention and Control Programs
• Stephen Mac, University of Toronto
Using Real-World Data and Multi-state Modelling to Inform a Health Economic Model of Late-Stage Prostate Cancer
• Dr. Nicholas Mitsakakis, University of Toronto/University Health Network
10:45 a.m. to 12:00 p.m.Concurrent Session E3 – Oral Presentations
Hot Topics
When Less Means More: Insight into the Spending on Expensive Drugs for Rare Diseases
• Jared Berger, PMPRB
Can We Afford to Screen and Treat Hepatitis C Virus Infection in Canada? Latest Insight From a Canadian Policy Model: A Province-by-Province Analysis
• Dr. William W.L. Wong, University of Waterloo
A Full CART of Learnings on System Implementation for Breakthrough Therapies
• Dr. Sherrie Hertz, Cancer Care Ontario
Uptake of the Ontario Naloxone Program for Pharmacies
• Diana Martins, Ontario Drug Policy Research Network
10:45 a.m. to 12:00 p.m.Concurrent Session E4– Oral Presentations
Rural And Remote Health Care
Furthering the Case for the Spread and Scale of Evidence-Based Remote Consult Services Across Health Systems: Results and Lessons from a Pan-Canadian Initiative
• Neil Drimer, Canadian Foundation for Healthcare Improvement
Assessing Colorectal Cancer Screening in Northern Canada Using Participatory Simulation Modelling
• Dr. Heather Smith, University of Ottawa
10:45 a.m. to 12:00 p.m.Concurrent Session E5 – Oral Presentations
Genetics And Genomics
The 3-I Framework: Considerations for Developing Regulations for Direct-to-Consumer Genetic Testing in Canada
• Alexandra Cernat, University of Toronto
Projecting the Utilization of Clinical Genetics Services in Canada: A Demand Model
• Dr. Nick Dragojlovic, University of British Columbia
Exploring the Adoption of Genomic Sequencing in Canada: A Qualitative Descriptive Study
• Salma Shickh, St. Michael’s Hospital
Health Technology Management in Genomics: Managing the Need to Recontact Patients as Genomics Results Change Over Time
• Dr. Yvonne Bombard, Li Ka Shing Knowledge Institute
10:45 a.m. to 12:00 p.m.Concurrent Session E6 – Oral Presentations
Data Sources
Should Medico-Administrative Data Be Used as a Source of Real-World Evidence in Health Technology Assessment?
• Laurie Lambert, INESSS
Mapping Canadian Data Assets to Conduct Real-World Studies: Lessons Learned From the CanREValue Real-World Evidence Data Working Group
• Dr. Claire de Oliveira, CAMH
• Wei Fang Dai, Cancer Care Ontario
Connecting Patients and Policies: How Registries Can Lay the Groundwork for New Treatments
• Dr. Chad Andrews, Fighting Blindness Canada
12:00 p.m. to 1:00 p.m.Networking Lunch
1:00 p.m. to 2:15 p.m.Concurrent Session F1 – Panel Discussion
The Evolution of Health Technology Assessment: How Must Canadian Stakeholders Adapt to the Use of Pharmacoeconomic Analyses for Regulatory Pricing Decisions?
• Beena Kuriakose, Janssen Inc.
• Wayne Critchley, Global Public Affairs
• Dr. Chris Cameron, EVERSANA
1:00 p.m. to 2:15 p.m.CONCURRENT SESSION F2 – PANEL DISCUSSION
Translating Research to Inform Policy Decisions: The OncoSim’s Experience
• Jean Hai Ein Yong, Canadian Partnership Against Cancer
• Dr. Heather Anne Smith, The Ottawa Hospital
• Dr. Catherine Popadiuk, Memorial University of Newfoundland
1:00 p.m. to 2:15 p.m.CONCURRENT SESSION F3 – PANEL DISCUSSION
Guidelines Don’t Self-Implement — How Can Implementation Science Help?
• Dr. Mina Tadrous, Women's College Hospital
• Dr. Laura Desveaux, Women’s College Hospital
• Dr. Noah Ivers, Women’s College Hospital
• Emily Nicholas Angl, Patient
1:00 p.m. to 2:15 p.m.CONCURRENT SESSION F4 – PANEL DISCUSSION
Crowd-Sourcing the Design of an Observational Study Using Patient Registry Data/Real-World Evidence to Address Uncertainties for a Drug Granted Marketing Authorization on the Basis of Phase II Data
• Dr. Anil Kapoor, Kidney Cancer Research Network of Canada, Kidney Cancer Canada
• Ranjena Maloni, Kidney Cancer Research Network of Canada
• Dr. Mona Sabharwal, Rexall Pharmacy Group Ltd.
• Dr. Alice Dragomir, Montreal General Hospital
2:15 p.m. to 2:45 p.m.Networking Break
2:45 p.m. to 4:00 p.m.Closing Plenary
Pharmaceutical Management In An Age Of Uncertainty
Pharmaceutical management in Canada is facing a perfect storm of change, with political and policy uncertainty, a desire for formulary modernization, new curative treatments, affordability issues, and other issues and pressures. How does pharmaceutical management need to evolve in order to improve patient outcomes and maintain health system sustainability?
4:00 p.m. to 4:30 p.m.Official Closing

* Dinner in the Clouds
Monday, April 20, 2020

6:00 p.m. to 9:00 p.m. (Buses depart from the Sheraton Centre at 5:30 p.m.)

Join us at the CN Tower for a spectacular evening of fun, food, and breathtaking views. You’ll arrive at 346 metres above ground to the LookOut level where you’ll take in the unparalleled scenes of Toronto through the new floor-to-ceiling panoramic Window Walls and you can take a look straight down below you through the Glass Floor. Enjoy hors d’oeuvres and dinner from the CN Tower’s award-winning menu that showcases the best Canadian and Ontario-specific food and beverages. Prepare yourself for an informal networking evening with amazing sights, delicious food, and unique entertainment.